Emyria Accelerates National Expansion with Institutional Backing and Key Strategic Milestones.
Emyria Limited (ASX: EMD) has advanced its national growth strategy with a series of major milestones supported by an AU$8 million institutional placement. The company exercised its Mornington Option, securing exclusive negotiation rights to establish its first Empax Clinic in Victoria within Avive Health’s flagship mental-health hospital. The strengthened agreement with Avive provides exclusive nationwide negotiation rights and reinforces Emyria’s capital-light rollout model. Revenue generation has commenced at the Brisbane Empax Clinic, validating the scalability of its evidence-based, clinician-led treatment model.
The recent decision by the Department of Veterans’ Affairs to fund medication-assisted psychotherapy, combined with existing Medibank pathways, creates Australia’s first dual-payer reimbursement framework. Backed by strong institutional demand, Emyria is poised to accelerate East Coast expansion, enhance clinical capacity, and build a predictable, recurring revenue base through CY2026.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au.au
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Emyria Accelerates National Expansion with Institutional Backing and Key Strategic Milestones.
Emyria Limited (ASX: EMD) has advanced its national growth strategy with a series of major milestones supported by an AU$8 million institutional placement. The company exercised its Mornington Option, securing exclusive negotiation rights to establish its first Empax Clinic in Victoria within Avive Health’s flagship mental-health hospital. The strengthened agreement with Avive provides exclusive nationwide negotiation rights and reinforces Emyria’s capital-light rollout model. Revenue generation has commenced at the Brisbane Empax Clinic, validating the scalability of its evidence-based, clinician-led treatment model.
The recent decision by the Department of Veterans’ Affairs to fund medication-assisted psychotherapy, combined with existing Medibank pathways, creates Australia’s first dual-payer reimbursement framework. Backed by strong institutional demand, Emyria is poised to accelerate East Coast expansion, enhance clinical capacity, and build a predictable, recurring revenue base through CY2026.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au.au